Core Viewpoint - The pharmaceutical stocks have risen significantly, driven by regulatory changes from the National Medical Products Administration (NMPA) aimed at expediting the approval of urgently needed foreign drugs in China [1] Group 1: Stock Performance - Stocks such as Akeso-B (01167) increased by 8.71% to HKD 7.24, HAPO (02142) rose by 7.61% to HKD 14.28, Innovent Biologics (02696) gained 5.25% to HKD 67.2, and InnoCare Pharma-B (09606) climbed 4.88% to HKD 365.6 [1] Group 2: Regulatory Changes - On January 7, the NMPA announced measures to optimize the review and approval process for urgently needed foreign drugs already on the market, aiming to meet the clinical needs of patients [1] - The NMPA emphasized a clinical value-oriented approach, encouraging applicants to conduct global synchronized research and simultaneous submissions for market approval in China [1] - The NMPA will prioritize the review of urgently needed foreign original and generic drugs that meet specific criteria [1] Group 3: Market Outlook - Huatai Securities believes that the valuation of innovative drugs in the Hong Kong market remains attractive compared to global peers, attributing the recent decline in innovative drug stocks to liquidity discounts [1] - The firm anticipates that the ongoing liquidity recovery, along with external business development (BD) activities, the JPMorgan Healthcare Conference, and the annual report cycle, will boost the innovative drug sector's performance [1] - The upward trend in the innovative drug sector is expected to continue as liquidity improves [1]
港股异动 | 医药股再度走高 国家药监局进一步优化审评审批 机构看好创新药迎多重催化